• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis.

作者信息

Tourkantonis A, Nicolaidis P

出版信息

J Antimicrob Chemother. 1983 Jul;12 Suppl A:263-7. doi: 10.1093/jac/12.suppl_a.263.

DOI:10.1093/jac/12.suppl_a.263
PMID:6352629
Abstract

The pharmacokinetics of ceftazidime were studied in 12 patients during peritoneal dialysis. In five patients given 1 g iv the mean serum levels (mg/l) at 0.25, 2 and 12 h after starting peritoneal dialysis were 50.6 +/- 11.2, 35.6 +/- 3.7 and 22.7 +/- 7.9, respectively. The mean ceftazidime peak level was 13.2 +/- 5.5 mg/l in peritoneal effluent, approximately 3 h after start of dialysis. The peritoneal clearance was 9 ml/min and the mean half-life during and after peritoneal dialysis was 8.7 +/- 3.1 h and 26.9 +/- 11 h, respectively. In four patients, 1 g ceftazidime was given via an intraperitoneal catheter. The mean serum levels (mg/l) at 0.25, 2 and 8 h were 14.2 +/- 3.1, 40.0 +/- 13.0 and 32.5 +/- 6.4 respectively. In three patients given ceftazidime 200 mg, in 21 dialysate treatments each with 12 cycles, mean serum levels increased from 1.3 +/- 1.5 mg/l at 1 h to 25.3 +/- 3.1 mg/l at 12 h. Mean levels in the dialysis effluent were 47.2 +/- 14.3 mg/l and the mean percentage of the dose recovered in the effluent was 47.1%. We concluded that (1) 1 g ceftazidime as an iv bolus maintained serum and peritoneal effluent levels adequate to treat patients; (2) its peritoneal absorption produced high ceftazidime levels in serum; (3) in infected patients undergoing peritoneal dialysis ceftazidime may be given either by the intravenous or intraperitoneal route.

摘要

相似文献

1
Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis.
J Antimicrob Chemother. 1983 Jul;12 Suppl A:263-7. doi: 10.1093/jac/12.suppl_a.263.
2
Pharmacokinetics of intravenous and intraperitoneal cefuroxime in patients undergoing peritoneal dialysis.腹膜透析患者静脉注射和腹腔注射头孢呋辛的药代动力学
Clin Nephrol. 1981 Jul;16(1):40-3.
3
Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.头孢孟多在接受血液透析和腹膜透析患者中的药代动力学。
Antimicrob Agents Chemother. 1976 Sep;10(3):457-61. doi: 10.1128/AAC.10.3.457.
4
Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis.
J Clin Pharmacol. 1993 May;33(5):475-9. doi: 10.1002/j.1552-4604.1993.tb04691.x.
5
Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis.头孢呋辛在持续非卧床腹膜透析和间歇性腹膜透析中的药代动力学
Nephron. 1985;41(2):161-5. doi: 10.1159/000183573.
6
Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1985 Sep;38(3):285-9. doi: 10.1038/clpt.1985.172.
7
Pharmacokinetics of intravenous and intraperitoneal cefuroxime during peritoneal dialysis.头孢呋辛在腹膜透析期间静脉注射和腹腔注射的药代动力学
Int J Clin Pharmacol Ther Toxicol. 1982 Feb;20(2):92-4.
8
Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患者腹腔内注射头孢他啶后的处置与生物利用度
J Am Soc Nephrol. 1996 Nov;7(11):2399-402. doi: 10.1681/ASN.V7112399.
9
Effect of hemodialysis on ceftazidime pharmacokinetics.血液透析对头孢他啶药代动力学的影响。
Clin Nephrol. 1985 Sep;24(3):142-6.
10
[Pharmacokinetics of cefoperazone in end-stage renal failure patients on peritoneal dialysis].
Jpn J Antibiot. 1986 Oct;39(10):2775-9.

引用本文的文献

1
Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.对持续不卧床腹膜透析患者头孢他啶剂量推荐的重新评估。
Antimicrob Agents Chemother. 2014;58(1):19-26. doi: 10.1128/AAC.00873-13. Epub 2013 Oct 14.
2
Cefepime clinical pharmacokinetics.头孢吡肟的临床药代动力学。
Clin Pharmacokinet. 1993 Aug;25(2):88-102. doi: 10.2165/00003088-199325020-00002.
3
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.接受腹膜透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
4
Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢他啶。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1985 Feb;29(2):105-61. doi: 10.2165/00003495-198529020-00002.
5
Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.持续非卧床腹膜透析患者中头孢吡肟的药代动力学
Antimicrob Agents Chemother. 1992 Jul;36(7):1387-91. doi: 10.1128/AAC.36.7.1387.